F9
Coagulation factor IX
As of the edition of 20 October 2026, F9 (coagulation factor IX, UniProt P00740) has 6 drugs tested at it and 6 companies on the list, 2 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P00740
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Secreted
- Solved structures
- 63
- Disease areas
- Inherited and neonatal; Blood and lymph; Heart and blood vessels; Nervous system; Nutrition and metabolism; Immune system; Bones, joints and muscles; Injuries
- Registered trials of its drugs
- 44
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Stopped | 3 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Emicizumab | Marketed | Phase 4 | Ends 2029 |
| Pegnivacogin | Stopped | Phase 3 | none listed |
| Levacetylleucine | Marketed | Phase 3 | Ends 2031 |
| TTP889 | Stopped | Phase 2 | none listed |
| Anivamersen | Stopped | Phase 3 | none listed |
| Factor ix complex | Marketed | Phase 1 | Ended 1982 |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 2 |
| Undetermined | 2 |
| Total on the list | 6 |
| Company | Route |
|---|---|
| IntraBio | Route B |
| Regado Biosciences | Route A |
| Roche | Route B |
The other 3 companies at F9
In the product6 companies in all; 3 are not named here, and no score is.
See the 6 companies at F9, ranked, with the facts behind eachRequest access. Nothing is shown until you do.